← Back to all trials
Completed
NCT01065727
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Conditions: Multiple Sclerosis
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 144
Sponsor: Rennes University Hospital
Location: CHU Cavale Blanche Brest
Summary
Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis
Eligibility Criteria
Inclusion Criteria:
* Patients with remitting multiple sclerosis according to mac Donald criteria
* aggressive remitting multiple sclerosis according to following criteria:
* 2 or less disabling relapse during the 12 months before inclusion
* 1 or more
* EDSS between 2 and 5
* aged less or equal to 40 years old for the women
* effective contraception
Exclusion Criteria:
* patients less than 18 years old
Source: ClinicalTrials.gov (NCT01065727). StuddyBuddy aggregates publicly available trial information.
